Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289789 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL3381887 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL27723864 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL7797764 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL3386054 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL3385773 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL28776473 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL2287183 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL1270406 | 0.96 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL1270542 | 0.96 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054664-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | Neurochem, Inc. (CA) | 2000-11-29 | — | — | EP | claimed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | claimed |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | disclosed |
| US-7754761-B2 | Sulfonated compounds and compositions for treating amyloidosis | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20070265334-A1 | Method for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20060167095-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-07-27 | — | — | US | disclosed |
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-0814842-B1 | METHOD FOR TREATING AMYLOIDOSIS | UNIV KINGSTON (CA) | 2005-10-12 | — | — | EP | disclosed |
| US-20040208875-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20030108595-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON | 2003-06-12 | — | — | US | disclosed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | disclosed |
| EP-1054664-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | Neurochem, Inc. (CA) | 2000-11-29 | — | — | EP | disclosed |
| US-5972328-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING GLYCEROL TRISULFURIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1999-10-26 | — | — | US | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
| US-5858326-A | CONTACTING AMYLOIDOGENIC PEPTIDE WITH AMYLOID-ENHANCING COMPOUND COMPRISING AROMATIC MOIETY AND AT LEAST TWO ANIONIC MOIETIES IN VITRO TO FORM AMYLOID FIBRILS | NEUROCHEM, INC. (CA) | 1999-01-12 | — | — | US | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
| US-5728375-A | ADMINISTERING A COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE; INHIBITS DEPOSITION BY PREVENTING INTERACTION BETWEEN AN AMYLOIDOGENIC PROTEIN AND A BASEMENT MEMBRANE CONSTITUENT | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-03-17 | — | — | US | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167095-A1 | Method for treating amyloidosis | TTR, IAPP, APP | APP 3/4885PTGS1 3896/4885PDE4A 4579/4885 |
| US-20070265334-A1 | Method for treating amyloidosis | TTR, IAPP, APP | APP 3/4885PTGS1 3896/4885PDE4A 4579/4885 |
| US-20030108595-A1 | Method for treating amyloidosis | TTR, IAPP, APP | APP 3/4885PTGS1 3896/4885PDE4A 4579/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | APP 5/4885PTGS1 3988/4885PDE4A 4653/4885 |
| US-20040208875-A1 | Method for treating amyloidosis | TTR, IAPP, APP | APP 3/4885PTGS1 3896/4885PDE4A 4579/4885 |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | TTR, IAPP, APP | APP 3/4885PTGS1 3896/4885PDE4A 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.